ArticleScience progress
Association between blood inflammatory biomarkers and mortality in individuals with self-reported obstructive sleep apnea symptoms: A nationwide population-based retrospective cohort study.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveTo investigate the associations of blood inflammatory biomarkers with all-cause and cardiovascular disease (CVD) mortality in individuals with self-reported obstructive sleep apnea (OSA) symptoms.MethodsThis retrospective cohort study included 10,230 adults aged ≥18 years with self-reported OSA symptoms from the NHANES database.Participants were followed from baseline through December 31, 2019. Kaplan-Meier analysis, multivariable Cox proportional hazards models, restricted cubic spline (RCS), segmented regression and sensitivity analyses were employed to evaluate the associations of inflammatory biomarkers, including red blood cell distribution width (RDW), RDW-to-albumin ratio (RAR), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) with all-cause and CVD mortality.ResultsKaplan-Meier analysis showed that survival rates were significantly lower among individuals with self-reported OSA symptoms who had the highest levels of RDW, RAR, NLR, and MLR. In the fully adjusted Cox model, the highest quartile (Q4) of these biomarkers was associated with significantly increased risks of all-cause mortality compared with the lowest quartile (Q1): RDW (HR=3.70; 95% CI:2.14-6.42), RAR (HR=2.93; 95% CI:2.20-3.91), NLR (HR=1.65; 95% CI: 1.32-2.07), and MLR (HR=1.68; 95% CI:1.22-2.31). For CVD mortality, the corresponding HRs (Q4 vs. Q1) were: RDW (HR=3.07; 95% CI:1.61-5.85), RAR (HR=2.99; 95% CI:1.57-5.68), NLR (HR=2.66; 95% CI:1.51-4.68), and MLR (HR=1.87; 95% CI:1.07-3.29). RCS model demonstrated that there was a nonlinear association between RDW, RAR, NLR and the both mortality endpoints, while MLR did not show a significant nonlinear relationship with mortality. Segmented regression further identified data-driven statistical thresholds. These exploratory, data-driven thresholds have not been clinically validated and should not be directly applied to clinical decision-making. Sensitivity analyses yielded consistent results.ConclusionsBlood inflammatory biomarkers (RDW, RAR, NLR, MLR) are significantly associated with all-cause and CVD mortality in individuals with self-reported OSA symptoms. Given the observational design, these biomarkers should be regarded as associative rather than prognostic, pending future confirmation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.